Adaptive Data Reconciliation Coupling C plus plus and PRO/II and On-line Application by the Field

被引：0
|
作者：
Manenti, Flavio [1 ]
Signor, Stefano [2 ]
Grottoli, Maria Grazia [2 ]
Fabbri, Paolo [2 ]
机构：
[1] Politecn Milan, CMIC Dept Giulio Natta, Piazza Leonardo da Vinci 32, I-20133 Milan, Italy
[2] Chemprod Srl Automat & Proc Solut, I-20129 Milan, Italy
来源：
20TH EUROPEAN SYMPOSIUM ON COMPUTER AIDED PROCESS ENGINEERING | 2010年 / 28卷
关键词：
Adaptive Data Reconciliation; Parameter Estimation; Sulfur Recovery; OPTIMIZATION; MODELS;
D O I：
暂无
中图分类号：
TQ [化学工业];
学科分类号：
0817 ;
摘要：
The paper discusses the possibility of coupling object-oriented programming languages such as Visual C++ and the commercial simulators such as PRO/II, UniSim, and AspenHysys to get a generalized framework for robust and reliable data reconciliation of sulfur recovery units by taking to a series of benefits from their interaction: (i) simulation software provides a high-level and field-proven degree of detail in simulating processes; (ii) they usually allow inferring measures even when the instrumentation presents serious lacks by the field; and (iii) the programming languages allow using specific numerical libraries to solve large-scale, nonlinear, constrained optimization problems by making them feasible even for the on-line industrial application. The proposed approach was validated on a large-scale Sulfur Recovery Unit (technology by Technip-KTI SpA) operating in an oil refinery placed in Italy.
引用
收藏
页码：373 / 378
页数：6
相关论文
共 50 条
  • [41] TOLERABILITY AND EFFICACY OF FIRST-LINE POLICHEMOTHERAPY (PCT) WITH PACLITAXEL PLUS BEVACIZUMAB IN PATIENTS (PTS) WITH METASTATIC BREAST CANCER C-ERB NEGATIVE. A PHASE II STUDY IN OUR INSTITUTION
    Cotroneo, G.
    Roda, G.
    Galmozzi, A.
    Mauri, C.
    Cabral, Duluc M.
    Nastasi, G.
    ANNALS OF ONCOLOGY, 2009, 20
  • [42] The GAIN-C study (BP25438): Randomized phase II trial of RG7160 (GA201) plus FOLFIRI, compared to cetuximab plus FOLFIRI or FOLFIRI alone in second-line KRAS wild type (WT) or mutant metastatic colorectal cancer (mCRC).
    Cervantes-Ruiperez, Andres
    Markman, Ben
    Siena, Salvatore
    Pericay, Carles
    Aprile, Giuseppe
    Bridgewater, John A.
    Cubillo, Antonio
    Waterston, Ashita Marie
    Garcia-Carbonero, Rocio
    Kozloff, Mark
    McKendrick, Joseph James
    Samuel, Leslie M.
    Perez-Fidalgo, Jose Alejandro
    Strickland, Andrew H.
    Bencardino, Katia
    Moya, Irene
    Lutrino, Stefania Eufemia
    Mancao, Christoph
    Manenti, Luigi
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] Docetaxel (D) plus prednisone (P) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line chemotherapy in metastatic hormone refractory prostate cancer (HRPC): Phase II clinical trial with pharmacodynamic evaluation
    Fontana, A.
    Bocci, G.
    D'Arcangelo, M.
    Galli, L.
    Galli, C.
    Bursi, S.
    Landi, L.
    Antonuzzo, A.
    Del Tacca, M.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] DOCETAXEL (D) PLUS PREDNISONE (P) IN COMBINATION WITH METRONOMIC CYCLOPHOSPHAMIDE (CTX) AND CELECOXIB (C) AS FIRST LINE TREATMENT IN METASTATIC HORMONE REFRACTORY PROSTATE CANCER (MHRPC): A PHASE II CLINICAL TRIAL WITH PHARMACODYNAMIC EVALUATION
    Fontana, A.
    Bocci, G.
    D'Arcangelo, M.
    Galli, L.
    Bursi, S.
    Landi, L.
    Battaglini, P.
    Caponi, S.
    Del Tacca, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 198 - 199
  • [45] 12-MONTH SURVIVAL DATA OF A PHASE II TRIAL: FIRST LINE TREATMENT OF INOPERABLE PANCREATIC ADENOCARCINOMA WITH CATIONIC LIPID COMPLEXED PACLITAXEL NANOPARTICLES (ENDOTAG-1®) PLUS GEMCITABINE COMPARED WITH GEMCITABINE MONOTHERAPY
    Loehr, Matthias
    Haas, Stephan
    Bechstein, Wolf-Otto
    Bodoky, Gyoergy
    Jaeger, Dirk
    Karrasch, Matthias
    Mescheder, Axel
    Meyer, Ines
    Pap, Akos
    Foelsch, Ulrich
    ANNALS OF ONCOLOGY, 2008, 19 : 2 - 3
  • [46] Zanidatamab plus chemotherapy for first-line (1L) treatment of HER2+advanced or metastatic gastro-oesophageal adenocarcinoma (mGEA): New and updated data from a phase II trial
    Elimova, E.
    Ajani, J. A.
    Burris, H. A.
    Denlinger, C. S.
    Iqbal, S.
    Kang, Y-K.
    Kim, J. H.
    Lee, K-W.
    Lin, B.
    Mehta, R.
    Oh, D-Y.
    Rha, S. Y.
    Seol, Y. M.
    Xie, C.
    Garfin, P.
    Ku, G. Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S887 - S888
  • [47] Clinical genotyping and efficacy outcomes: Exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer
    Pallaud, Celine
    Reck, Martin
    Juhasz, Erzsebet
    Szima, Barna
    Yu, Chung-Jen
    Burdaeva, Olga
    Orlov, Sergey
    Hilton, Magalie
    Archer, Venice
    Mok, Tony
    LUNG CANCER, 2014, 86 (01) : 67 - 72
  • [48] Updated results from the multicenter phase II, ALTER-C001 trial: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC
    Jin, Y.
    Han, Y.
    Zhang, L.
    Jin, Y.
    Sun, H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S720 - S721
  • [49] Survival data from EMPOWER-Lung 4: Phase II study of cemiplimab plus ipilimumab in the second-line (2L) treatment of advanced non-small cell lung cancer (NSCLC)
    Shim, B. Y.
    Lee, S.
    de Castro Carpeno, J.
    Chiu, C-H.
    Cobo, M.
    Kim, H. R.
    Ryu, J. S.
    Majem Tarruella, M.
    Summers, Y.
    Thomas, C. A.
    Xu, Y.
    Lowy, I.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S760 - S760
  • [50] Intermittent Chemotherapy (CT) Plus Continuous or Intermittent Cetuximab (C) in the First-line Treatment of Advanced Colorectal Cancer (aCRC): Results of the Two-arm Phase II Randomised MRC COIN-B Trial
    Wasan, H.
    Adams, R. A.
    Wilson, R. H.
    Pugh, C. A.
    Fisher, D.
    Madi, A.
    Sizer, B.
    Butler, R.
    Meade, A.
    Maughan, T. S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S393 - S393
12345